Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-08-20 00:00:00 ET · period of report 2024-08-19 · accession 0001649094-24-000054 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-20 | 2024-08-19 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $5.35 | +8,000 | 104.7K | +8% | +$42.8K |
| DM | 2024-08-20 | 2024-08-19 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | S - Sale+OE | $78.58 | -8,000 | 99.7K | -7% | -$628.7K |
| D | 2024-08-20 | 2024-08-19 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $0.00 | -8,000 | 328.8K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-19 | M | A | 8,000 | $5.35 | 104,720 | D | — | — | |
| 2 | Common | Common Stock | 2024-08-19 | S | D | 3,006 | $79.14 | 96,720 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $78.88 to $79.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-08-19 | S | D | 4,994 | $78.25 | 99,726 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $77.875 to $78.78. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 4 | Derivative | Stock Option (right to buy) | 2024-08-19 | M | D | 8,000 | $0.00 | 328,827 | D | $5.35 · — to 2030-05-11 | 8,000 Common Stock | (F4) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |